Depressive Disorder News and Research RSS Feed - Depressive Disorder News and Research

Study shows non-Hispanic blacks less likely to receive treatment for schizophrenia

Study shows non-Hispanic blacks less likely to receive treatment for schizophrenia

Non-Hispanic blacks are almost twice as likely as non-Hispanic whites to be diagnosed with schizophrenia, but they're significantly less likely to receive medication for treatment, according to researchers. [More]
Study demonstrates effectiveness of NeuroStar TMS Therapy System in women with postpartum depression

Study demonstrates effectiveness of NeuroStar TMS Therapy System in women with postpartum depression

An unfortunate fact facing mothers in the U.S. is that postpartum depression is the most common complication of childbirth. Approximately 10 to 15 percent of women who give birth each year – or roughly 600,000 women – experience postpartum depression symptoms. [More]
New study links altered purine metabolism to major depressive disorder

New study links altered purine metabolism to major depressive disorder

People suffering from major depressive disorder may have altered purine metabolism, according to a new study from the University of Eastern Finland and Kuopio University Hospital. [More]
Low adiponectin levels may lead to development of PTSD symptoms

Low adiponectin levels may lead to development of PTSD symptoms

Individuals with post-traumatic stress disorder (PTSD) relive past traumas again and again, bound in a virtual prison of their memories. [More]
Study shows risk of developing MDD depends on symptom centrality in network

Study shows risk of developing MDD depends on symptom centrality in network

A novel study published in the current issue of Psychotherapy and Psychosomatics discloses how depression may develop. [More]

Mindfulness-based cognitive therapy more beneficial without antidepressant drugs

An investigation published in the current issue of Psychotherapy and Psychosomatics indicates that mindfulness based cognitive therapy (MBCT) is most helpful when antidepressant drugs are not used. [More]
Neuroimaging studies offer new insights into cognitive vulnerability to depression

Neuroimaging studies offer new insights into cognitive vulnerability to depression

Neuroimaging studies of interconnected brain networks may provide the "missing links" between behavioral and biological models of cognitive vulnerability to depression, according to a research review in the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer. [More]
Depressed moms not physiologically 'in sync' with their children

Depressed moms not physiologically 'in sync' with their children

Mothers with a history of depression are not physiologically "in sync" with their kids, according to a new study from Binghamton University. While researchers have known for a while that depression is associated with interpersonal problems with others, this is the first study to examine whether this is also evident physiologically. [More]
RADAR-CNS programme aims to improve lives of patients with brain disorders

RADAR-CNS programme aims to improve lives of patients with brain disorders

A major new research program supported by the Innovative Medicines Initiative launches today, which will develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. [More]
New meta-analysis supports link between intake of omega-3 fatty acids and reduction in MDD

New meta-analysis supports link between intake of omega-3 fatty acids and reduction in MDD

According to the World Health Organization, depression is a major cause of disease burden worldwide, affecting an estimated 350 million people. According to the National Institutes of Mental Health, in 2014, an estimated 15.7 million adults aged 18 or older in the United States had at least one major depressive episode in the past year. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
New imaging study shows how exercise affects the brain

New imaging study shows how exercise affects the brain

People who exercise have better mental fitness, and a new imaging study from UC Davis Health System shows why. Intense exercise increases levels of two common neurotransmitters -- glutamate and gamma-aminobutyric acid, or GABA -- that are responsible for chemical messaging within the brain. [More]
Researchers explore effects of attention bias modification in adolescents with MDD

Researchers explore effects of attention bias modification in adolescents with MDD

A study to be published in the March 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry reports that adolescents with major depression who performed a computer-based task designed to shift attention from sad to neutral to positive word associations showed reductions in negative attention biases and clinician-rated depressive symptoms. [More]
Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015. [More]
Study: People with schizophrenia more likely to attempt suicide

Study: People with schizophrenia more likely to attempt suicide

A new study by the University of Toronto, released today, found that those with schizophrenia who'd been physically abused during childhood were five times more likely to have attempted suicide. [More]

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD). [More]
Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Researchers of a new study published in the current issue of Biological Psychiatry report successful reduction of depressive symptoms in patients using a novel non-invasive method of vagus nerve stimulation, or VNS. [More]
People injured by police officers more likely to have mental illness

People injured by police officers more likely to have mental illness

People hospitalized due to an encounter with a law enforcement officer are more likely to have a mental illness, have longer hospitalizations, more injuries to the back and spine, and greater need for extended care than those hospitalized due to altercations with other civilians. [More]
Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD). [More]
Study provides better understanding of familial risk for depression

Study provides better understanding of familial risk for depression

Building on a 30-year, three-generation study of depressed individuals, their children and offspring, a study published in the journal Psychiatry Research: Neuroimaging provides a better understanding of the familial risk for depression and the role neuroplasticity might have in increasing the risk of developing depression. [More]
Advertisement
Advertisement